CN106420876A - Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid - Google Patents
Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid Download PDFInfo
- Publication number
- CN106420876A CN106420876A CN201611007041.9A CN201611007041A CN106420876A CN 106420876 A CN106420876 A CN 106420876A CN 201611007041 A CN201611007041 A CN 201611007041A CN 106420876 A CN106420876 A CN 106420876A
- Authority
- CN
- China
- Prior art keywords
- receptaculum helianthi
- water extract
- filtrate
- uric acid
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 22
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229940116269 uric acid Drugs 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000694 effects Effects 0.000 title abstract description 20
- 150000002632 lipids Chemical class 0.000 title abstract description 4
- 230000035622 drinking Effects 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 title abstract 6
- 230000003247 decreasing effect Effects 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 28
- 239000000706 filtrate Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 10
- 239000002245 particle Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 235000013361 beverage Nutrition 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 abstract description 7
- 235000003222 Helianthus annuus Nutrition 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000208818 Helianthus Species 0.000 abstract 4
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000011085 pressure filtration Methods 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 description 11
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 244000269722 Thea sinensis Species 0.000 description 7
- 229960003459 allopurinol Drugs 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 229960002529 benzbromarone Drugs 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
The invention relates to a drinking liquid with uric acid decreasing and lipid lowering effects and a preparation method of the drinking liquid. The drinking liquid contains a sunflower disc water extract which is diluted to 500 ml with a proper amount of water, wherein the sunflower disc water extract is prepared through the following steps: (1) crushing 200 g of the sunflower disc water extract into blocky particles with the size being 1.5 cm, adding 5 times the amount of water for soaking the blocky particles for 2-3 hours, performing extraction by ultra-high pressure equipment in 500-700 Pa of pressure for 5-15 minutes at the room temperature, performing pressure filtration, and concentrating a filtrate to the crude drug dose; (2) adding ethanol with the concentration of 50% and in a volume 2 times that of the filtrate to the concentrated filtrate for alcohol precipitation for 12 hours, taking a supernatant, and heating the supernatant to recover ethanol to obtain the sunflower disc water extract. The drinking liquid has remarkable uric acid decreasing and lipid lowering effects, has small toxic and side effects and can be taken for a long time.
Description
Technical field
The invention belongs to the field of Chinese medicines is and in particular to a kind of uric acid resisting Antilipemic beverage and preparation method thereof.
Background technology
Hyperuricemia, also known as gout, refers to that in human body, urate generates excessive or renal excretion uric acid minimizing, thus drawing
The gouty acute arthritises recurrent exerbation rising uric acid in blood salinity to raise and leading to, tophaceous deposition, tophaceous are slow
Property arthritis and joint deformity etc..It is now recognized that the reason cause hyperuricemia is mainly due to edible excessive high purine
Food, such as pluck, seafood, chicken and duck Carnis Anseris domestica, Carnis Coturnicis japonicae, pigeon etc..In terms for the treatment of, the method that Western medicine there is no radical cure,
Though the medicines such as conventional anti-gout drugs Colchicine, nonsteroidal antiinflammatory drug, allopurinol can mitigation symptoms, reduce hematuria
Acid, but its effect is more single, is difficult to fundamentally treat gout, and the injury that long-term taking causes to body is more than therapeutic effect
Many.
China's theory of Chinese medical science thinks：Floral disc of sunflower, the property of medicine is sweet, cold, return liver warp, function The flat liver of heat-clearing, analgesic hemostatic；Main
Control hypertension, headache and dizzy, tinnitus, dysmenorrhea, metrorrhagia, sore rash.It is additionally, since in Receptaculum Helianthi and contain in most Chinese herbal medicine
Common are effect chemical composition, such as chlorogenic acid, flavone, saccharide, volatile oil, trace element etc., Cai Yong of Jilin University et al. is
Receptaculum Helianthi is studied further, and points out that Receptaculum Helianthi hydrolysis compound powder not only has blood uric acid liter in potential prevention animal body
High effect, also has simultaneously and reduces potentiality effect (CN201510589245.7) having formed metabolic arthritis level in blood.
Therefore, it is necessary to make further research to Receptaculum Helianthi extraction process etc. so as to antihyperuricemic can be treated in preparation
Extensively apply in the medicine of disease.
Content of the invention
It is an object of the invention to provide a kind of brand-new Receptaculum Helianthi extracting method, thus prepare a kind of uric acid resisting lipid-lowering effect
Significantly, toxic and side effects are little, can long-term taking drink.
For achieving the above object, technical scheme of the present invention is realized in：This uric acid resisting Antilipemic beverage includes
Following raw materials：
Receptaculum Helianthi water extract, suitable quantity of water is settled to 500ml；
Wherein, the preparation method of described Receptaculum Helianthi water extract is as follows：
(1) 200g Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, adds 5 times amount water to soak 2-3 hour,
5-15 minute, filter pressing is extracted with extra-high tension unit under 500-700 handkerchief pressure, filtrate is concentrated into 200ml under room temperature；
(2) add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, heat back
Receive ethanol, obtain Receptaculum Helianthi water extract.
For improving the therapeutic effect of drink of the present invention further, improve the mouthfeel of drink, improve body to medicine
Absorption rate, also can comprise tea polysaccharide 1-3g in described drink；Vitamin C 0.2-0.5g.
It is a further object of the present invention to provide a kind of preparation method of uric acid resisting Antilipemic beverage, specifically include following steps：
(1) weigh 200g Receptaculum Helianthi, Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, add 5 times amount water to soak
2-3 hour, is extracted 10 minutes under 600 handkerchief pressure with extra-high tension unit, filter pressing, filtrate is concentrated into crude drug amount at normal temperatures；
(2) add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, heat back
Receive ethanol, obtain the aqueous solution of pure Receptaculum Helianthi water extract；
(3) tea polysaccharide and vitamin C are added in the aqueous solution of the prepared Receptaculum Helianthi water extract of step (2), stir,
Add water and be settled to 500ml, fill obtains final product.
Advantages of the present invention and good effect：
(1) present invention is due to adopting elevated pressures, and solvent can penetrate into intracellular in very short time, makes effective ingredient fast
Speed reaches dissolution equilibrium, substantially increases the extraction efficiency of Receptaculum Helianthi effective ingredient；Simultaneously as carrying out at room temperature, maximum
Limit remain bioactive substance in Receptaculum Helianthi, therefore, prepared beverage uric acid resisting lipid-lowering effect more preferably, toxic and side effects
Little, patient can take for a long time.
(2) pass through in beverage of the present invention to add tea polysaccharide and vitamin C, can not only Receptaculum Helianthi be carried enhancing body
Take the absorption of thing, heighten the effect of a treatment, simultaneously can also reduction blood fat, improve blood glucose, thus reduce suffer from diabetes and cardiovascular disease
Risk.
(3) make drink after above-mentioned raw materials are mixed by the present invention, considerably increase the absorption to medicine for the body, rapid-action,
And preparation process is simple, beverage clarity, good stability, mouthfeel is good, improves the compliance of patient.
Specific embodiment
Embodiment 1
(1) weigh 200 grams of Receptaculum Helianthi, Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, add 5 times amount water loggings
Bubble 2-3 hour, (20 DEG C) are extracted 10 minutes under 600 handkerchief pressure with extra-high tension unit at normal temperatures, filter pressing, and filtrate is concentrated into
200ml；
(2) add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, using rotation
Turn evaporimeter and heat (40 DEG C -45 DEG C) recovery ethanol, obtain the aqueous solution 200ml of pure Receptaculum Helianthi water extract, add water and be settled to
500ml, fill obtains final product.
Embodiment 2
(1) weigh 200 grams of Receptaculum Helianthi, Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, add 5 times amount water loggings
Bubble 2-3 hour, (20 DEG C) are extracted 10 minutes under 600 handkerchief pressure with extra-high tension unit at normal temperatures, filter pressing, and filtrate is concentrated into life
Dose；
(2) add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, using rotation
Turn evaporimeter and heat (40 DEG C -45 DEG C) recovery ethanol, obtain the aqueous solution 200ml of pure Receptaculum Helianthi water extract；
(3) 3g tea polysaccharide is added in the aqueous solution of the prepared Receptaculum Helianthi water extract of step 2, stir, add water constant volume
To 500ml, fill obtains final product.
Embodiment 3
(1) weigh 200 grams of Receptaculum Helianthi, Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, add 5 times amount water loggings
Bubble 2-3 hour, (20 DEG C) are extracted 10 minutes under 600 handkerchief pressure with extra-high tension unit at normal temperatures, filter pressing, and filtrate is concentrated into life
Dose；
(2) add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, using rotation
Turn evaporimeter and heat (40 DEG C -45 DEG C) recovery ethanol, obtain the aqueous solution 200ml of pure Receptaculum Helianthi water extract；
(3) 3g tea polysaccharide and 0.5g vitamin C are added in the aqueous solution of the prepared Receptaculum Helianthi water extract of step 2, stirring
Uniformly, add water and be settled to 500ml, fill obtains final product.
Comparative example 1
(1) weigh 200g Receptaculum Helianthi, Receptaculum Helianthi is pulverized (60 mesh), add 3-5 times amount water to soak 2-3 hour, then heat
Reflux, extract, 2 hours, filters, and filtrate concentrates；
(2) add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, using rotation
Turn evaporimeter and heat (40 DEG C -45 DEG C) recovery ethanol, concentrate, obtain Receptaculum Helianthi water extract about 200ml；
(3) 3g tea polysaccharide and 0.5g vitamin C are settled to 500ml with Receptaculum Helianthi water extract mixing and water adding in step 2,
Fill.
Drink drug effect data of the present invention：
1st, materials and methods
1.1 laboratory animal
Kunming mouse, male, body weight 19～21g, provided by preclinical medicine institute of Jilin University animal experimental center.
1.2 medicines and reagent
The drink of the present invention；Benzbromarone:Yichang Changjiang Pharmaceutical Co., Ltd.；Allopurinol:The auspicious pharmacy of Chongqing section (collection
Group) company limited.
The impact to hyperuricemia rat for 1.3 drinks
Male mouse of kunming is divided into matched group and hyperuricemia group [lumbar injection oxonic acid potassium salt method (300mg/kg
Disposable celiac drug administration by injection) preparation hyperuricemia animal model].Hyperuricemia group is randomly divided into model group, benzene again
Xiu Malong treatment group, allopurinol treatment group, uric acid resisting Antilipemic beverage treatment group, treatment group give respectively Benzbromarone 20mg/kg,
Allopurinol 40mg/kg, uric acid resisting lipid-loweringing beverage 15ml/kg, gavage, after 7 days, observes each group mice blood uric acid, blood lipid level becomes
Change.
2nd, result
The impact to hyperuricemia rat for 2.1 drinks of the present invention, is shown in Table 1 to table 4.
The impact to hyperuricemia rat for table 1 embodiment 1 drink
The impact to hyperuricemia rat for table 2 embodiment 2 drink
The impact to hyperuricemia rat for table 3 embodiment 3 drink
The impact to hyperuricemia rat for table 4 comparative example 1 drink
From table 1 to table 3, the embodiment of the present invention 1 is all better than Benzbromarone to drink uric acid resisting effect described in embodiment 3
With allopurinol, meanwhile, also above Benzbromarone and allopurinol in reduction cholesterol, the ability of triacylglycerol, add tea
Polysaccharide contributes to reducing cholesterol and triacylglycerol, increases vitamin C and considers because of increased the absorption to medicine for the mice,
Thus further enhancing the effect reducing uric acid and cholesterol and triacylglycerol it can be seen that, drink of the present invention has concurrently
Uric acid resisting and the double effects of blood fat reducing.
As shown in Table 4, Receptaculum Helianthi water extract has the effect of uric acid resisting really, has reduction cholesterol and trigalloyl concurrently simultaneously
The effect of glycerol, but take its action effect of Receptaculum Helianthi water extract difference that different techniques are obtained larger it is considered to may be by
Destroy some bioactive substances when using heating and refluxing extraction, and be the behaviour of comparative example 1 according to general extraction methods
Make step, find that the final water extract obtaining greatly reduces it is considered to it could also be possible that the active substance in Receptaculum Helianthi is not complete
Entirely extract causing it can be seen that, the extraction process of Receptaculum Helianthi is larger on the impact of its therapeutic effect it is therefore necessary to strict control
Extraction process processed, makes effective ingredient fully extract, and also will ensure that it is not destroyed, and it so just can be made to play your writing
With.
Claims (3)
1. a kind of uric acid resisting Antilipemic beverage it is characterised in that：Described drink includes Receptaculum Helianthi water extract, and suitable quantity of water is settled to
500ml；
Wherein, the preparation method of described Receptaculum Helianthi water extract is as follows：
（1）200g Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, adds 5 times amount water to soak 2-3 hour, in room temperature
Lower use extra-high tension unit extracts 5-15 minute, filter pressing under 500-700 handkerchief pressure, and filtrate is concentrated into crude drug amount；
（2）Add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, heating recovery second
Alcohol, obtains Receptaculum Helianthi water extract.
2. a kind of uric acid resisting Antilipemic beverage according to claim 1 it is characterised in that：Tea polysaccharide is also included in described drink
1-3 g；Vitamin C 0.2-0.5 g.
3. a kind of preparation method of uric acid resisting Antilipemic beverage it is characterised in that：Comprise the following steps：
（1）Weigh 200g Receptaculum Helianthi, Receptaculum Helianthi is ground into the blocky-shaped particle of 1-1.5cm size, add 5 times amount water to soak 2-3
Hour, extracted 10 minutes under 600 handkerchief pressure with extra-high tension unit at normal temperatures, filter pressing, filtrate is concentrated into crude drug amount；
（2）Add the ethanol that 2 times amount concentration are 50%, precipitate with ethanol 12 hours in filtrate after concentration, take supernatant, heating recovery second
Alcohol, obtains the aqueous solution of pure Receptaculum Helianthi water extract；
（3）Tea polysaccharide and vitamin C are added step（2）In the prepared aqueous solution of Receptaculum Helianthi water extract, stir, add water
It is settled to 500ml, fill obtains final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611007041.9A CN106420876A (en) | 2016-11-16 | 2016-11-16 | Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611007041.9A CN106420876A (en) | 2016-11-16 | 2016-11-16 | Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420876A true CN106420876A (en) | 2017-02-22 |
Family
ID=58208049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611007041.9A Pending CN106420876A (en) | 2016-11-16 | 2016-11-16 | Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420876A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106668657A (en) * | 2017-03-03 | 2017-05-17 | 孙龙喜 | Beverage capable of lowering uric acid and lipid and preparation method of beverage |
| CN108379318A (en) * | 2018-05-31 | 2018-08-10 | 吉林大学 | It is a kind of with the floral disc of sunflower water extract of xanthine oxidase inhibitory activity, preparation method and applications |
| CN108902980A (en) * | 2018-09-19 | 2018-11-30 | 吉林省恒实传食品科技发展有限公司 | A kind of prevention and treatment hyperuricemia and health care's combined food of gout and preparation method thereof |
| RU2683570C1 (en) * | 2018-05-23 | 2019-03-29 | Евгений Иванович Верещагин | Composition for vegetable components, which has the ability to reduce the level of uric acid in blood serum |
| CN112891386A (en) * | 2021-03-19 | 2021-06-04 | 北京奇诺生物科技有限公司 | Composition for reducing blood uric acid and preparation method and application thereof |
| CN112933126A (en) * | 2021-03-19 | 2021-06-11 | 北京奇诺生物科技有限公司 | Composition for preventing and treating hyperuricemia and preparation method and application thereof |
| CN114377050A (en) * | 2022-02-15 | 2022-04-22 | 吉林大学 | Anti-gout composition containing sunflower disc micromolecules |
| CN114885996A (en) * | 2022-05-20 | 2022-08-12 | 福建糖小六生物科技有限公司 | Seven-wind tea with uric acid reducing function and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101323649A (en) * | 2008-08-04 | 2008-12-17 | 南方李锦记有限公司 | Method for extracting mushroom polysaccharide by using ultra-high pressure |
| CN105920067A (en) * | 2016-05-06 | 2016-09-07 | 洮南市金塔生物科技有限公司 | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract |
-
2016
- 2016-11-16 CN CN201611007041.9A patent/CN106420876A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101323649A (en) * | 2008-08-04 | 2008-12-17 | 南方李锦记有限公司 | Method for extracting mushroom polysaccharide by using ultra-high pressure |
| CN105920067A (en) * | 2016-05-06 | 2016-09-07 | 洮南市金塔生物科技有限公司 | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract |
Non-Patent Citations (3)
| Title |
|---|
| 刘小波等: "一种抗痛风中草药葵花盘粉的药理作用", 《内蒙古中医药》 * |
| 刘清等: "向日葵副产物资源的综合利用", 《农业工程学报》 * |
| 罗永明: "《中药化学成分提取分离技术与方法》", 31 January 2016, 上海科学技术出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106668657A (en) * | 2017-03-03 | 2017-05-17 | 孙龙喜 | Beverage capable of lowering uric acid and lipid and preparation method of beverage |
| RU2683570C1 (en) * | 2018-05-23 | 2019-03-29 | Евгений Иванович Верещагин | Composition for vegetable components, which has the ability to reduce the level of uric acid in blood serum |
| CN108379318A (en) * | 2018-05-31 | 2018-08-10 | 吉林大学 | It is a kind of with the floral disc of sunflower water extract of xanthine oxidase inhibitory activity, preparation method and applications |
| CN108902980A (en) * | 2018-09-19 | 2018-11-30 | 吉林省恒实传食品科技发展有限公司 | A kind of prevention and treatment hyperuricemia and health care's combined food of gout and preparation method thereof |
| CN112891386A (en) * | 2021-03-19 | 2021-06-04 | 北京奇诺生物科技有限公司 | Composition for reducing blood uric acid and preparation method and application thereof |
| CN112933126A (en) * | 2021-03-19 | 2021-06-11 | 北京奇诺生物科技有限公司 | Composition for preventing and treating hyperuricemia and preparation method and application thereof |
| CN114377050A (en) * | 2022-02-15 | 2022-04-22 | 吉林大学 | Anti-gout composition containing sunflower disc micromolecules |
| CN114885996A (en) * | 2022-05-20 | 2022-08-12 | 福建糖小六生物科技有限公司 | Seven-wind tea with uric acid reducing function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106420876A (en) | Drinking liquid with uric acid decreasing and lipid lowering effects and preparation method of drinking liquid | |
| CN106668657A (en) | Beverage capable of lowering uric acid and lipid and preparation method of beverage | |
| CN105530928B (en) | Prevent and treat the pharmaceutical composition of the fat and fat metabolic syndrome induced | |
| TWI740030B (en) | Composition comprising plant extracts and the use thereof for promoting gene expression of glut4 | |
| CN104666996B (en) | Refresh oneself antifatigue Chinese medicine composition and preparation method and application | |
| CN108042627A (en) | A kind of composition for dropping hyperuricemia and its preparation method and application | |
| Sunday et al. | Hypoglycemic, hypolipidemic and body weight effects of unripe pulp of Carica papaya using diabetic Albino rat model. | |
| CN106038670A (en) | Preparation method of Vaccinium dunalianum Wight extract | |
| CN106360219A (en) | Preparation method of honeysuckle beverage | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN107007646A (en) | A kind of nutrition compound of assisting in preventing and treating cancer | |
| CN106511968A (en) | Selenium-rich oral solution with effects of reducing blood sugar, reducing blood fat and boosting immunity and preparation method thereof | |
| CN102068557B (en) | Application of Pu'er tea extract in preparation of medicines for reducing blood fat | |
| CN107823258A (en) | Preparation method, cinnamomum cassia extract and its application of cinnamomum cassia extract | |
| CN107198170A (en) | A kind of preparation formula of natural raspberry composite oral liquid | |
| WO2020000828A1 (en) | Gracilaria lemaneiformis polysaccharide having significant hypolipidemic activity and preparation method therefor and use thereof | |
| CN107280006A (en) | It is a kind of that there is hypoglycemic, blood fat reducing function composition, beverage and its application | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN103478843B (en) | A kind of alcohol-decomposing beverage and preparation method thereof | |
| El-Shaer et al. | Effect of Intake of Garcinia Cambogia Peels on Induced-Obesity Rats | |
| CN106924581A (en) | It is a kind of to treat medicinal liquor of stomachache and preparation method thereof | |
| CN103804392B (en) | Two kinds of terphenyls dioxazines derivative and application thereof | |
| CN105325983A (en) | Microcapsule containing royal jelly and sea buckthorn and preparation method of microcapsule | |
| CN107441429A (en) | A kind of sobering-up composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |